Alterity Therapeutics (ASX:ATH) has taken a step forward in its effort to develop a treatment for one of the most challenging neurodegenerative disorders, Multiple System Atrophy.
The company announced that it has received encouraging feedback from the United States Food and Drug Administration following a recent Type C meeting, marking a significant moment in its clinical development journey
The meeting was part of a broader regulatory strategy to align the company’s plans with the FDA before advancing into a pivotal Phase 3 trial.
According to Alterity, the agency’s written response supported key aspects of its program, particularly in clinical pharmacology and nonclinical development. This alignment reduces uncertainty as the company prepares for the next stage of testing its lead drug candidate, ATH434
Chief Executive Officer David Stamler described the outcome as an important milestone, noting that agreement in these foundational areas helps pave the way for further discussions with regulators. The company said it still intends to seek additional clarity on manufacturing standards and the detailed design of the Phase 3 trial, with a formal end-of-Phase 2 meeting expected in the middle of 2026. That upcoming interaction will bring together all remaining elements needed to start the late-stage study.